| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 06/19/2001 | US6248753 Bicyclic compounds |
| 06/19/2001 | US6248745 Mixture comprising a cyclooxygenase-2 (cox-2) inhibitor and a 1,2-dihydro-4-aminoquinazoline derivative inhibitor of induced nitric oxide synthase (inos); non-steroidal antiinflammatory agents |
| 06/19/2001 | US6248713 Cell adhesion inhibitors |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248557 RatC |
| 06/19/2001 | US6248390 Fiber-water—water containing soluble fiber |
| 06/19/2001 | US6248368 Administering magnesium salt |
| 06/19/2001 | US6248365 Use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | US6248347 Calcium assimilation accelerator and calcium-supplementing diet comprising and a method for accelerating calcium assimilation |
| 06/19/2001 | US6248335 Ph control |
| 06/19/2001 | CA2218616C Nitrosylated neuropeptides |
| 06/19/2001 | CA2125964C Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists |
| 06/19/2001 | CA2040248C Method of inhibiting gastric acid secretion |
| 06/19/2001 | CA1341260C Pharmaceutical and/or dietary compsitions containing l-carnitine and l- lysine |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042449A2 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042281A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | WO2001042273A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/14/2001 | WO2001042272A2 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | WO2001042263A2 Oligosaccharide mixture |
| 06/14/2001 | WO2001042255A1 (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL |
| 06/14/2001 | WO2001042252A1 New aminopropylphosphinic acids |
| 06/14/2001 | WO2001042247A1 Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same |
| 06/14/2001 | WO2001042246A2 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| 06/14/2001 | WO2001042244A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 06/14/2001 | WO2001042241A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | WO2001042238A1 Heterocyclic derivatives |
| 06/14/2001 | WO2001042225A2 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042216A2 Caspase inhibitors and uses thereof |
| 06/14/2001 | WO2001042215A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | WO2001042213A1 Urea compounds having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042212A1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042207A2 Novel methods for the treatment and prevention of ileus |
| 06/14/2001 | WO2001042205A2 Treatment of inflammatory bowel disease with vitamin d compounds |
| 06/14/2001 | WO2001042193A1 β2-ADRENERGIC RECEPTOR AGONISTS |
| 06/14/2001 | WO2001042191A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/14/2001 | WO2001042189A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 06/14/2001 | WO2001041801A2 Mutant simplex virus for treating unwanted hyperproliferative cell growth |
| 06/14/2001 | WO2001041794A2 Activated amylase |
| 06/14/2001 | WO2001041785A2 Enzyme treatment for infection |
| 06/14/2001 | WO2001041776A2 Use of honey in medical dressings |
| 06/14/2001 | WO2001041766A1 The combination of a serotonin reuptake inhibitor and irindalone |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041753A2 Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds |
| 06/14/2001 | WO2001041748A2 Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| 06/14/2001 | WO2001041743A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | WO2001041701A2 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001041535A2 Eplerenone crystalline form |
| 06/14/2001 | WO2001027101A3 Anhydrous salt |
| 06/14/2001 | WO2001018040A3 Use of leptin in inhibition of endothelial cell proliferation |
| 06/14/2001 | WO2001017989A3 Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists |
| 06/14/2001 | WO2001005773A8 Conjugates of sodium channel blockers and methods of using the same |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | US20010003749 Arylpiperazines having activity at the serotonin 1A receptor |
| 06/14/2001 | US20010003747 Useful in treating or in preventing melatoninergic disorders |
| 06/14/2001 | US20010003742 Antilipemic formulation |
| 06/14/2001 | CA2733434A1 Caspase inhibitors and uses thereof |
| 06/14/2001 | CA2396739A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393510A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | CA2393470A1 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | CA2393141A1 Novel methods for the treatment and prevention of ileus |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2392566A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | CA2390859A1 Treatment of inflammatory bowel disease with vitamin d compounds |
| 06/14/2001 | CA2388959A1 Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | CA2362845A1 Eplerenone crystalline form |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2362669A1 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | CA2361647A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106608A1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 06/13/2001 | EP1105503A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1) |
| 06/13/2001 | EP1105501A2 Tpl-2/cot kinase and methods of use |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105422A1 Hepatitis c inhibitor peptides |
| 06/13/2001 | EP1105421A2 Anti-inflammatory peptides derived from il-2 and analogues thereof |
| 06/13/2001 | EP1105414A2 Synthetic peptides and methods of use for autoimmune disease therapies |
| 06/13/2001 | EP1105413A2 Hepatitis c inhibitor tri-peptides |
| 06/13/2001 | EP1105409A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 06/13/2001 | EP1105401A1 Phosphoglycolipid and methods for its use |
| 06/13/2001 | EP1105391A2 New compounds |
| 06/13/2001 | EP1105390A2 New compounds |
| 06/13/2001 | EP1105389A1 Integrin receptor antagonists |
| 06/13/2001 | EP1105387A1 Prodrugs of proton pump inhibitors |
| 06/13/2001 | EP1105386A1 Novel salt form of pantoprazole |
| 06/13/2001 | EP1105384A1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors |